title: Lapatinib for the treatment of breast cancer in the People's Republic of China.
abstract: Lapatinib is an oral, small-molecule, reversible inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor-2 (HER2) tyrosine kinases. In March 2007, the US Food and Drug Administration approved lapatinib for use in combination with capecitabine for the treatment of women with HER2-overexpressing, advanced or metastatic breast cancer. This review discusses the available information of lapatinib in Chinese breast cancer patients, focusing on its effectiveness and clinical application against advanced or metastatic breast cancer. In pivotal phase III trials, a combination of lapatinib and capecitabine significantly decreased the risk of disease progression compared to capecitabine alone in women with HER2-positive advanced or metastatic breast cancer. Other trials were used to evaluate lapatinib in combination with hormone therapy, in combination with trastuzumab, and as an adjunct to adjuvant therapy for early-stage disease. Preclinical data have revealed that lapatinib is active in trastuzumab-resistant cell lines as well as synergistic with trastuzumab. In clinical trials, lapatinib has not been associated with serious or symptomatic cardiotoxicity. Further, it can cross the blood-brain barrier and may therefore have a role in preventing cancer progression in the central nervous system. Thus, lapatinib warrants further evaluation in HER2-positive metastatic and early-stage breast cancer patients.
authors.affiliation: Department of Breast Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.
authors.forename: Hongjiang
authors.initials: H
authors.lastname: Wang
keywords: HER2 positive; breast cancer; lapatinib; molecular targeting therapy
references.citation: J Clin Oncol. 2004 Mar 15;22(6):1063-70
references.pmid: 15020607
references.citation: Nat Clin Pract Oncol. 2006 May;3(5):269-80
references.pmid: 16683005
references.citation: Oncologist. 2006 Apr;11(4):318-24
references.pmid: 16614227
references.citation: Asian Pac J Cancer Prev. 2010;11(4):913-7
references.pmid: 21133600
references.citation: Drug Metab Dispos. 2009 Feb;37(2):439-42
references.pmid: 19056914
references.citation: J Clin Oncol. 2014 Jul 1;32(19):2039-49
references.pmid: 24868024
references.citation: J Cancer Res Clin Oncol. 2010 Sep;136(9):1389-400
references.pmid: 20217132
references.citation: N Engl J Med. 2009 Sep 3;361(10):947-57
references.pmid: 19692680
references.citation: N Engl J Med. 2005 Jul 14;353(2):123-32
references.pmid: 16014882
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2306-12
references.pmid: 17538177
references.citation: Lancet Oncol. 2013 Jan;14(1):88-96
references.pmid: 23234763
references.citation: Oncogene. 2009 Feb 12;28(6):803-14
references.pmid: 19060928
references.citation: Cancer Res. 2007 Feb 1;67(3):1170-5
references.pmid: 17283152
references.citation: Cancer Res. 2006 Feb 1;66(3):1630-9
references.pmid: 16452222
references.citation: Ann Surg Oncol. 2009 Oct;16(10):2705-10
references.pmid: 19593632
references.citation: Med Oncol. 2012 Dec;29(5):3232-9
references.pmid: 22729366
references.citation: Exp Mol Med. 2013 Nov 22;45:e64
references.pmid: 24263233
references.citation: Breast Cancer Res Treat. 2009 Oct;117(3):577-89
references.pmid: 19153829
references.citation: Oncologist. 2006 Nov-Dec;11(10):1047-57
references.pmid: 17110623
references.citation: Cancer Res. 2001 Oct 1;61(19):7196-203
references.pmid: 11585755
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2502-12
references.pmid: 15684311
references.citation: Cancer Res. 2004 Sep 15;64(18):6652-9
references.pmid: 15374980
references.citation: Lancet Oncol. 2008 Jan;9(1):23-8
references.pmid: 18083065
references.citation: Oncogene. 2011 Oct 6;30(40):4163-74
references.pmid: 21499296
references.citation: Cancer Res. 2005 Jan 1;65(1):18-25
references.pmid: 15665275
references.citation: Clin Cancer Res. 2009 Feb 15;15(4):1452-9
references.pmid: 19228746
references.citation: Nat Rev Cancer. 2011 May;11(5):352-63
references.pmid: 21472002
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Oncogene. 2004 Jan 22;23(3):646-53
references.pmid: 14737100
references.citation: Breast Cancer Res Treat. 2013 Nov;142(2):405-14
references.pmid: 24197661
references.citation: Pharm Res. 2012 Mar;29(3):770-81
references.pmid: 22011930
references.citation: Pharmacogenomics. 2007 Jun;8(6):567-75
references.pmid: 17559346
references.citation: Drug Metab Dispos. 2008 Apr;36(4):695-701
references.pmid: 18216274
references.citation: J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103
references.pmid: 18664652
references.citation: Clin Adv Hematol Oncol. 2007 Jun;5(6):456-8
references.pmid: 17679920
references.citation: Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10607-12
references.pmid: 17556544
references.citation: Breast Cancer Res Treat. 2012 Jun;133(2):511-21
references.pmid: 21947749
references.citation: Chin J Cancer. 2011 May;30(5):327-35
references.pmid: 21527065
references.citation: Oncogene. 2002 Sep 12;21(41):6255-63
references.pmid: 12214266
references.citation: Onco Targets Ther. 2014 Feb 13;7:245-51
references.pmid: 24611017
references.citation: Nat Chem Biol. 2013 May;9(5):307-12
references.pmid: 23502424
references.citation: Mol Cancer Ther. 2007 Feb;6(2):667-74
references.pmid: 17308062
references.citation: Breast Cancer Res Treat. 2008 Dec;112(3):533-43
references.pmid: 18188694
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: Arch Pathol Lab Med. 2007;131(1):18-43
references.pmid: 19548375
references.citation: Mol Cancer Ther. 2001 Dec;1(2):85-94
references.pmid: 12467226
references.citation: Breast Cancer. 2015 Sep;22(5):503-9
references.pmid: 24385387
references.citation: Ann Pharmacother. 2006 Feb;40(2):261-9
references.pmid: 16418322
references.citation: Oncologist. 2009 Apr;14(4):320-68
references.pmid: 19346299
references.citation: Nat Rev Drug Discov. 2011 Feb;10(2):111-26
references.pmid: 21283106